
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 20 years ago
Case Studyalmost 20 years ago
CME/CE Quizalmost 20 years ago
Health Outcomes Beyond Glucose Controlalmost 20 years ago
Introductionalmost 20 years ago
Oral Combination Therapy with Thiazolidinediones in Type 2 Diabetes





